USPTO Examiner SCHMIDT EMILY LOUISE - Art Unit 3783

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18601200AutoinjectorMarch 2024August 2024Allow520YesNo
18601243AutoinjectorMarch 2024July 2024Allow410YesNo
18428682DISINFECTION CAP FOR IV NEEDLELESS CONNECTORSJanuary 2024January 2025Allow1210NoNo
18396812CATHETER ASSEMBLYDecember 2023December 2024Allow1210NoNo
18392152Basket For A Catheter DeviceDecember 2023December 2024Allow1110NoNo
18479260SYRINGE PUMP WITH FLANGE CLAMP SENSOROctober 2023May 2025Allow1910NoNo
18463963DRUG DELIVERY DEVICE AND CHARGING DEVICESeptember 2023January 2025Allow1610NoNo
18455444EXPANDABLE ECMO EXTENSION CANNULA SYSTEMAugust 2023September 2024Allow1310NoNo
18194166SYRINGE WITH PRIMING MECHANISMMarch 2023November 2024Allow1921YesNo
18164042Steerable Medical Device HandleFebruary 2023November 2024Allow2121YesNo
18151982EXPANDABLE ECMO EXTENSION CANNULA SYSTEMJanuary 2023April 2023Allow300NoNo
18092803CANNULA CAPTURE MECHANISMJanuary 2023April 2025Allow2721YesNo
18057595PERFUSION SYSTEMNovember 2022May 2024Allow1810NoNo
17977461DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATIONOctober 2022September 2024Allow2220NoNo
17977749AUTOINJECTOROctober 2022January 2024Allow1430YesNo
17972018SEQUENCED SYRINGE ASSEMBLYOctober 2022August 2024Allow2220YesNo
17958181Devices and Methods for Syringes Configured to Reduce or Eliminate Residual VolumeSeptember 2022February 2024Allow1620YesNo
17950916Interlocking Low Profile Gripping DeviceSeptember 2022April 2025Allow3020NoNo
17819735DRUG DELIVERY DEVICE AND METHODS HAVING A RETAINING MEMBERAugust 2022April 2024Allow2020YesNo
17872959DEVICES AND METHODS FOR PRECISION DOSE DELIVERYJuly 2022December 2023Allow1700YesNo
17864858DOSE SETTING DEVICE FOR AN INJECTION DEVICEJuly 2022February 2024Allow1920NoNo
17855494SECUREMENT DEVICE FOR POLYMER TUBING AND POLYMER COATED CABLESJune 2022December 2022Allow610NoNo
17843687GUIDE EXTENSION CATHETERJune 2022August 2024Abandon2621NoNo
17663205EXPANDABLE ECMO EXTENSION CANNULA SYSTEMMay 2022September 2022Allow400NoNo
17741651Using Alternating Electric Fields to Increase Permeability of the Blood Brain BarrierMay 2022February 2024Allow2220YesNo
17662702DEVICES, SYSTEMS, AND RELATED METHODS FOR DELIVERY OF FLUID TO TISSUEMay 2022February 2025Abandon3331NoNo
17688541Interlocking Low Profile Gripping DeviceMarch 2022May 2022Allow200NoNo
17686132CATHETER SYSTEM WITH GUIDEWIRE ADVANCEMENT ELEMENTMarch 2022January 2024Allow2311NoNo
17653115MODULAR BLOOD GLUCOSE CONTROL SYSTEMSMarch 2022June 2023Abandon1520YesNo
17652463CANNULAS FOR SYSTEMS AND METHODS FOR DELIVERING MICRODOSES OF MEDICATIONFebruary 2022February 2023Allow1220YesNo
17668071AUTOINJECTORFebruary 2022February 2024Abandon2510NoNo
17612591DRUG DELIVERY DEVICENovember 2021June 2025Abandon4301NoNo
17522129SYSTEM AND METHOD FOR IMPROVED GAS RECIRCULATION IN SURGICAL TROCARS WITH PNEUMATIC SEALINGNovember 2021March 2025Allow4051YesNo
17517464DEVICES AND METHODS FOR PRECISION DOSE DELIVERYNovember 2021May 2024Abandon3011NoNo
17516099DEVICES AND METHODS FOR DELIVERY OF SUBSTANCES WITHIN A PREFILLED SYRINGENovember 2021February 2024Allow2821YesNo
17451906CATHETER ASSEMBLYOctober 2021October 2023Allow2410NoNo
17493806Catheter Insertion Device Including Top-Mounted Advancement ComponentsOctober 2021October 2023Allow2510YesNo
17490689DRUG DELIVERY DEVICE FOR LIQUID PHARMACEUTICALSSeptember 2021January 2024Allow2810NoNo
17467552Medicament Delivery Device Having a Cap AssemblySeptember 2021September 2023Allow2410NoNo
17458878PRE-FILLED SYRINGE WITH OPTIMIZED STOPPER PLACEMENTAugust 2021May 2024Abandon3220NoYes
17400865SYRINGE INFUSION DEVICES AND SYSTEMS FOR DELIVERY OF ACTIVE AGENTSAugust 2021January 2024Abandon2910NoNo
17396037DISINFECTION CAP FOR IV NEEDLELESS CONNECTORSAugust 2021October 2023Allow2610NoNo
17376846BRAIDED CRESCENT RIBBON CATHETER REINFORCEMENTJuly 2021June 2024Abandon3521NoNo
17344764ASSEMBLY FOR DELIVERING AN AGENTJune 2021December 2024Abandon4301NoNo
17335974Securement DeviceJune 2021October 2023Allow2820YesNo
17330753SYSTEMS AND METHODS FOR DETECTING AND TREATING BACTERIAL BIOFILMSMay 2021March 2024Abandon3411NoNo
17327173Drug delivery deviceMay 2021April 2024Abandon3520NoNo
17244088NON-REUSABLE SYRINGE AND METHODS OF USEApril 2021September 2024Abandon4121NoNo
17234881MEDICAL NEEDLEApril 2021March 2025Allow4741NoNo
17232662EXPANDABLE CATHETER SYSTEM FOR PERI-OSTIAL INJECTION AND MUSCLE AND NERVE FIBER ABLATIONApril 2021December 2023Allow3220NoNo
17218875DEVICES AND METHODS FOR PRECISION DOSE DELIVERYMarch 2021April 2022Allow1330YesNo
17217199METHODS AND COMPOSITIONS RELATED TO PHYSIOLOGICALLY RESPONSIVE MICRONEEDLE DELIVERY SYSTEMSMarch 2021June 2023Allow2710NoNo
17215518BASKET FOR A CATHETER DEVICEMarch 2021September 2023Allow3011NoNo
17191442DEVICES, SYSTEMS AND METHODS FOR MEDICAMENT DELIVERYMarch 2021November 2023Abandon3210NoNo
17269510DEVICES AND METHODS FOR DELIVERY OF SUBSTANCES WITHIN A PREFILLED SYRINGEFebruary 2021July 2021Allow510NoNo
17178104SYSTEM AND METHOD FOR SAFETY SYRINGEFebruary 2021July 2024Allow4140NoNo
17174353Automated Seldinger Technique DeviceFebruary 2021October 2023Abandon3210NoNo
17170381Delivery Capsule with Threshold ReleaseFebruary 2021October 2023Abandon3311YesNo
17168882BYPASS CATHETERFebruary 2021October 2023Abandon3210NoNo
17156066COMPACT INJECTION DEVICE WITH TELESCOPING COMPONENTSJanuary 2021September 2024Allow4430YesNo
17127541PERFUSION SYSTEMDecember 2020November 2021Allow1120NoNo
17115414APPARATUS FOR INJECTING INFUSION SOLUTIONDecember 2020December 2023Abandon3620YesNo
16972504PNEUMATIC POWER PACKDecember 2020February 2024Allow3810NoNo
17111089MICROINJECTION CATHETERDecember 2020May 2024Allow4121YesNo
17110807DRUG DELIVERY DEVICE AND METHOD OF OPERATING THE DEVICEDecember 2020February 2025Allow5051YesNo
17106981DIALYSIS VALVE AND METHODNovember 2020March 2023Allow2710NoNo
17100363BYPASS CATHETERNovember 2020August 2023Abandon3310NoNo
17055677NEEDLE-FREE INJECTION SYSTEMNovember 2020November 2024Abandon4821NoNo
17097706NESTED SYRINGE ASSEMBLYNovember 2020April 2023Allow2910NoNo
17052653THERAPY DEVICES, METHODS, AND SYSTEMS INCLUDING A PISTON-STYLE DETECTORNovember 2020October 2023Allow3610NoNo
17080715FLUID INFUSION PATCH PUMP DEVICE WITH AUTOMATIC STARTUP FEATUREOctober 2020April 2025Abandon5441YesNo
17079159DEVICE FOR ADMINISTERING A FLUID PRODUCTOctober 2020February 2024Allow4020YesNo
17072411DRUG DELIVERY METHODS WITH TRACEROctober 2020August 2023Abandon3401NoNo
17063721HIGH FORCE INJECTION DEVICESOctober 2020November 2024Abandon4930NoNo
17034707SUB-RETINAL TANGENTIAL NEEDLE CATHETER GUIDE AND INTRODUCERSeptember 2020March 2023Allow3010YesNo
17032071BYPASS CATHETERSeptember 2020April 2023Allow3110NoNo
17011749MICROPUMPSeptember 2020August 2023Allow3621NoNo
17007086OPIOID OVERDOSE RESCUE DEVICEAugust 2020March 2024Allow4340YesYes
16998491NEUROLOGICAL APPARATUS COMPRISING A PERCUTANEOUS ACCESS DEVICEAugust 2020March 2023Allow3110NoNo
16992776INCREASED BIOAVAILABILITY OF TRANSDERMALLY DELIVERED AGENTSAugust 2020July 2024Allow4730YesNo
16990945MEDICAL DEVICES AND METHODS FOR FLUID TRANSFERAugust 2020March 2023Allow3110NoNo
16968790PEN NEEDLE AND INNER SHIELDAugust 2020October 2023Abandon3820YesNo
16984840LOW WASTE SYRINGE AND NEEDLE ASSEMBLAGEAugust 2020December 2023Allow4110NoNo
16940845Auto-Injector ApparatusJuly 2020October 2023Abandon3811NoNo
16941384SYRINGE PUMP WITH FLANGE CLAMP SENSORJuly 2020July 2023Allow3620YesNo
16947305Hypodermic Interface AssemblyJuly 2020November 2023Allow4041YesNo
16939796Non-Invasive Agent ApplicatorJuly 2020December 2023Allow4130YesNo
16938663ELECTRONIC PATCH FOR TRANSDERMAL DELIVERY OF MEDICAL COMPOSITIONSJuly 2020December 2023Abandon4120NoNo
16912407CATHETER PUNCTURE DEVICEJune 2020April 2023Abandon3420YesNo
16910176NEUROSURGICAL APPARATUS AND METHODSJune 2020May 2024Abandon4640NoNo
16908608Ultra-Low Waste Disposable Safety Syringe for Low Dose InjectionsJune 2020July 2022Allow2510NoNo
16900747DEVICES AND METHODS FOR PRECISION DOSE DELIVERYJune 2020April 2022Abandon2240YesNo
16772441DRUG DELIVERY DEVICE AND CHARGING DEVICEJune 2020June 2023Allow3620YesNo
16888277Intravenous System Including Pump, Vascular Access Device And Securement Device And Methods ThereofMay 2020January 2024Abandon4441YesNo
16881727BYPASS CATHETERMay 2020November 2022Allow3021YesNo
16880128MEDICAMENT DELIVERY DEVICE HAVING AN ELECTRONIC CIRCUIT SYSTEMMay 2020October 2022Abandon2910NoNo
16876420Gravity Infusion Control SystemMay 2020May 2023Abandon3610NoNo
16872230Handheld Drug Delivery DeviceMay 2020October 2023Allow4130NoNo
16869982BYPASS CATHETERMay 2020November 2022Allow3021YesNo
16868461Insertion DeviceMay 2020January 2025Allow5620NoYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SCHMIDT, EMILY LOUISE.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
23
Examiner Affirmed
13
(56.5%)
Examiner Reversed
10
(43.5%)
Reversal Percentile
65.7%
Higher than average

What This Means

With a 43.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
34
Allowed After Appeal Filing
12
(35.3%)
Not Allowed After Appeal Filing
22
(64.7%)
Filing Benefit Percentile
55.5%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 35.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner SCHMIDT, EMILY LOUISE - Prosecution Strategy Guide

Executive Summary

Examiner SCHMIDT, EMILY LOUISE works in Art Unit 3783 and has examined 415 patent applications in our dataset. With an allowance rate of 68.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner SCHMIDT, EMILY LOUISE's allowance rate of 68.7% places them in the 23% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SCHMIDT, EMILY LOUISE receive 2.43 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SCHMIDT, EMILY LOUISE is 32 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +21.3% benefit to allowance rate for applications examined by SCHMIDT, EMILY LOUISE. This interview benefit is in the 70% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 22.9% of applications are subsequently allowed. This success rate is in the 21% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 40.7% of cases where such amendments are filed. This entry rate is in the 55% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 22.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 26% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 47.7% of appeals filed. This is in the 9% percentile among all examiners. Of these withdrawals, 19.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 53.5% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 43% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.7% of allowed cases (in the 52% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.